您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Zenocutuzumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Zenocutuzumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1969309-56-5
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品名称
MCLA-128
PB4188
R040517
产品介绍
Zenocutuzumab (MCLA-128) 是一种双特异性人源化 IgG1 抗体,包含两个不同的 Fab 臂,靶向HER2HER3的细胞外结构域。
生物活性

Zenocutuzumab (MCLA-128) is a bispecific humanizedIgG1antibody containing two different Fab arms, targeting extracellular domains ofHER2andHER3[1].

体外研究
(In Vitro)

Zenocutuzumab(0.001-1000 nM;96 小时)抑制肺癌和乳腺癌细胞系的细胞生长[1]
Zenocutuzumab(0.1-1000 nM;24 小时)抑制 HER3 和 AKT 磷酸化,在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物[1]

Cell Viability Assay[1]

Cell Line:Human bronchiolar epithelial cell lines (HBEC)
Concentration:0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:96 h
Result:Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.

Western Blot Analysis[1]

Cell Line:HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:24 hours
Result:Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.
体内研究
(In Vivo)

Zenocutuzumab(2.5-25 mg/kg;腹腔注射;每周一次;持续 28 天)导致生长显着减少,包括肿瘤消退[1]

Animal Model:6 to 12-week-old female NSG(TM) (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1].
Dosage:2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:i.p.; once weekly; for 28 days
Result:Blocked growth of lung and ovarian cancer PDX models.
CAS 号

1969309-56-5

中文名称

泽妥珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.